Seattle Genetics Inc. (NASDAQ:SGEN) CEO Clay B. Siegall sold 14,465 shares of Seattle Genetics stock in a transaction on Monday, November 7th. The shares were sold at an average price of $58.43, for a total value of $845,189.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Clay B. Siegall also recently made the following trade(s):

  • On Thursday, October 6th, Clay B. Siegall sold 14,465 shares of Seattle Genetics stock. The shares were sold at an average price of $54.41, for a total value of $787,040.65.
  • On Thursday, September 8th, Clay B. Siegall sold 31,269 shares of Seattle Genetics stock. The shares were sold at an average price of $50.08, for a total value of $1,565,951.52.
  • On Monday, August 22nd, Clay B. Siegall sold 23,381 shares of Seattle Genetics stock. The shares were sold at an average price of $46.59, for a total value of $1,089,320.79.

Seattle Genetics Inc. (NASDAQ:SGEN) traded down 1.7333% during trading on Thursday, reaching $67.9711. The company had a trading volume of 1,008,225 shares. Seattle Genetics Inc. has a 1-year low of $26.02 and a 1-year high of $75.36. The firm has a 50-day moving average of $54.38 and a 200-day moving average of $45.60. The stock’s market capitalization is $9.62 billion.

Seattle Genetics (NASDAQ:SGEN) last posted its quarterly earnings results on Thursday, October 27th. The company reported ($0.23) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.29) by $0.06. Seattle Genetics had a negative return on equity of 16.27% and a negative net margin of 27.03%. The company had revenue of $106.30 million for the quarter, compared to analysts’ expectations of $4.34 million. During the same period last year, the firm earned ($0.21) earnings per share. Seattle Genetics’s quarterly revenue was up 26.4% on a year-over-year basis. On average, analysts anticipate that Seattle Genetics Inc. will post ($0.95) EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Seattle Genetics (NASDAQ:SGEN)

Hedge funds have recently bought and sold shares of the stock. BlackRock Inc. boosted its stake in Seattle Genetics by 283.9% in the first quarter. BlackRock Inc. now owns 11,654 shares of the company’s stock worth $408,000 after buying an additional 8,618 shares in the last quarter. BlackRock Group LTD boosted its stake in Seattle Genetics by 18.4% in the first quarter. BlackRock Group LTD now owns 102,261 shares of the company’s stock worth $3,589,000 after buying an additional 15,873 shares in the last quarter. State Street Corp boosted its stake in Seattle Genetics by 18.3% in the first quarter. State Street Corp now owns 2,319,710 shares of the company’s stock worth $81,406,000 after buying an additional 358,297 shares in the last quarter. Geode Capital Management LLC boosted its stake in Seattle Genetics by 7.9% in the first quarter. Geode Capital Management LLC now owns 711,458 shares of the company’s stock worth $24,965,000 after buying an additional 52,065 shares in the last quarter. Finally, Bellevue Group AG acquired a new stake in Seattle Genetics during the first quarter worth $2,386,000. Institutional investors own 97.21% of the company’s stock.

Several research analysts recently weighed in on SGEN shares. Leerink Swann restated a “buy” rating and set a $62.00 target price on shares of Seattle Genetics in a research note on Friday, September 16th. HC Wainwright restated a “buy” rating on shares of Seattle Genetics in a research note on Sunday, October 30th. Cantor Fitzgerald downgraded Seattle Genetics from a “buy” rating to a “hold” rating and set a $43.00 target price on the stock. in a research note on Wednesday, July 27th. JPMorgan Chase & Co. restated a “hold” rating and set a $43.00 target price on shares of Seattle Genetics in a research note on Monday, October 31st. Finally, TheStreet upgraded Seattle Genetics from a “sell” rating to a “hold” rating in a research note on Friday, October 28th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the company. The company has an average rating of “Hold” and an average price target of $51.53.

About Seattle Genetics

Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company’s product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC), comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE).

5 Day Chart for NASDAQ:SGEN

Receive News & Stock Ratings for Seattle Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics Inc. and related stocks with our FREE daily email newsletter.